You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Article metrics

Article menu

Download PDFPDF

XML
Short Report
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2024

AbstractFullPdf
Dec 2019660
Jan 2020881
Feb 2020661
Mar 2020992
Apr 202013131
May 202011110
Jun 202016162
Jul 202013136
Aug 20206617
Sep 202023234
Oct 2020232311
Nov 202012124
Dec 2020778
Jan 2021232314
Feb 202112129
Mar 202114145
Apr 2021121221
May 202113139
Jun 2021272716
Jul 202115154
Aug 2021141415
Sep 2021151513
Oct 2021333323
Nov 2021111119
Dec 202117176
Jan 202217189
Feb 2022121210
Mar 2022121211
Apr 202215156
May 20229912
Jun 202222237
Jul 202242432
Aug 2022272926
Sep 2022141714
Oct 2022111120
Nov 2022131310
Dec 202216165
Jan 2023141615
Feb 202317176
Mar 20238810
Apr 202391121
May 2023887
Jun 202317187
Jul 20238813
Aug 202312128
Sep 202318184
Oct 202310107
Nov 202323237
Dec 202316168
Jan 202423249
Feb 2024996
Mar 2024161621
Apr 2024121210
May 202410103
Jun 202417196
Jul 202427275
Aug 202418186
Total861877522